0001193125-22-199606.txt : 20220722 0001193125-22-199606.hdr.sgml : 20220722 20220722070202 ACCESSION NUMBER: 0001193125-22-199606 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220722 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220722 DATE AS OF CHANGE: 20220722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 221098418 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d383183d8k.htm FORM 8-K Form 8-K
false 0000860730 0000860730 2022-07-22 2022-07-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 22, 2022

 

 

HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-11239   27-3865930

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

One Park Plaza, Nashville,

Tennessee

   37203
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class

   

Trading

Symbol(s)

   

Name of each exchange

on which registered

Common Stock, $.01 par value per share    HCA    New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On July 22, 2022, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2022, the text of which is set forth as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On July 22, 2022, the Company issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2022, the text of which is set forth as Exhibit 99.1.

Item 8.01. Other Events.

On July 22, 2022, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.56 per share of the Company’s common stock. The dividend will be paid on September 30, 2022 to stockholders of record at the close of business on September 16, 2022.

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits:

 

Exhibit 99.1    Press Release, dated July 22, 2022
Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HCA HEALTHCARE, INC.
 

/s/ William B. Rutherford

 

William B. Rutherford

Executive Vice President and Chief Financial Officer

Date: July 22, 2022

EX-99.1 2 d383183dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO   LOGO

 

 

 

INVESTOR CONTACT:   

FOR IMMEDIATE RELEASE

MEDIA CONTACT:

Frank Morgan    Harlow Sumerford
615-344-2688    615-344-1851

HCA Healthcare Reports Second Quarter 2022 Results

Nashville, Tenn., July 22, 2022 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2022.

Key second quarter metrics (all percentage changes compare 2Q 2022 to 2Q 2021 unless otherwise noted):

 

  •  

Revenues totaled $14.820 billion

 

  •  

Net income attributable to HCA Healthcare, Inc. totaled $1.155 billion, or $3.90 per diluted share

 

  •  

Adjusted EBITDA totaled $3.042 billion

 

  •  

Cash flows from operating activities totaled $1.630 billion

 

  •  

Same facility admissions declined 1.2 percent and same facility equivalent admissions increased 0.5 percent

“Many aspects of our business were positive considering the challenges we faced with the labor market and other inflationary pressures on costs,” said Sam Hazen, Chief Executive Officer of HCA Healthcare. “Our teams executed well as they have in the past through other difficult environments. Again, I want to thank them for their dedication and excellent work.”

Revenues in the second quarter of 2022 increased to $14.820 billion, compared to $14.435 billion in the second quarter of 2021. Net income attributable to HCA Healthcare, Inc. totaled $1.155 billion, or $3.90 per diluted share, compared to $1.450 billion, or $4.36 per diluted share, in the second quarter of 2021. The second quarter of 2022 results include losses on sales of facilities of $32 million, or $0.11 per diluted share, and losses on retirement of debt of $78 million, or $0.20 per diluted share. The second quarter of 2021 results included gains on sales of facilities of $8 million, or $0.02 per diluted share, and losses on retirement of debt of $12 million, or $0.03 per diluted share.

For the second quarter of 2022, Adjusted EBITDA totaled $3.042 billion, compared to $3.219 billion in the second quarter of 2021. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions declined 1.2 percent and same facility equivalent admissions increased 0.5 percent in the second quarter of 2022, compared to the prior year period. Same facility emergency room visits increased 7.3 percent in the second quarter of 2022, compared to the prior year period. Same facility inpatient surgeries

 

1

declined 2.3 percent while same facility outpatient surgeries declined 1.4 percent in the second quarter of 2022, compared to the same period of 2021. Same facility revenue per equivalent admission increased 3.5 percent in the second quarter of 2022, compared to the second quarter of 2021.

Six Months Ended June 30, 2022

Revenues for the six months ended June 30, 2022 totaled $29.765 billion, compared to $28.412 billion in the same period of 2021. Net income attributable to HCA Healthcare, Inc. was $2.428 billion, or $8.05 per diluted share, compared to $2.873 billion, or $8.50 per diluted share, for the first six months of 2021. Results for the six months ended June 30, 2022 include losses on sales of facilities of $22 million, or $0.08 per diluted share, and losses on retirement of debt of $78 million, or $0.20 per diluted share. Results for the six months ended June 30, 2021 included gains on sales of facilities of $10 million, or $0.02 per diluted share, and losses on retirement of debt of $12 million, or $0.03 per diluted share.

Balance Sheet and Cash Flows from Operations

As of June 30, 2022, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $858 million, total debt of $38.903 billion, and total assets of $51.584 billion. During the second quarter of 2022, capital expenditures totaled $1.080 billion, excluding acquisitions. Cash flows provided by operating activities in the second quarter totaled $1.630 billion, compared to $2.251 billion in the second quarter of 2021.

During the second quarter of 2022, the Company repurchased 12.230 million shares of its common stock at a cost of $2.682 billion. The Company had $3.803 billion remaining under its repurchase authorization as of June 30, 2022. As of June 30, 2022, the Company had $2.725 billion of availability under its credit facilities.

Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share on the Company’s common stock. The dividend will be paid on September 30, 2022 to stockholders of record at the close of business on September 16, 2022.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.

Earnings Conference Call

HCA Healthcare will host a conference call for investors at 8:00 a.m. Central Daylight Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company’s Investor Relations web page at https://investor.hcahealthcare.com/events-and-presentations/default.aspx.

About the Company

As of June 30, 2022, HCA operated 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

 

2

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) developments related to COVID-19, including, without limitation, the length and severity of its impact and the spread of virus strains with new epidemiological characteristics; the volume of canceled or rescheduled procedures and the volume and acuity of COVID-19 patients cared for across our health systems; measures we are taking to respond to COVID-19; the impact and terms of government and administrative regulation and stimulus and relief measures (including the Families First Coronavirus Response Act, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, the Paycheck Protection Program and Health Care Enhancement Act, the Consolidated Appropriations Act, 2021, the American Rescue Plan Act of 2021 (“ARPA”) and other enacted and potential future legislation) and whether various stimulus and relief programs continue or new similar programs are enacted in the future; changes in revenues due to declining patient volumes, changes in payer mix and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions, including the impact of any current or future vaccine mandates; supply shortages and disruptions; and the timing, availability and adoption of effective medical treatments and vaccines (including boosters), (2) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, (3) the impact of current and future federal and state health reform initiatives and possible changes to other federal, state or local laws and regulations affecting the health care industry, including but not limited to, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), and the effects of additional changes to the Affordable Care Act, its implementation, or interpretation (including through executive orders and court challenges), and proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), and also including any such laws or governmental regulations which are adopted in response to COVID-19, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions and those required under the Pay-As-You-Go Act of 2010 (“PAYGO Act”) as a result of the federal budget deficit impact of the ARPA, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) increases in

 

3

wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) changes in general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy and financial markets) resulting from COVID-19 or other factors, (16) the emergence of and effects related to pandemics, epidemics and infectious diseases, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (21) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of potential cybersecurity incidents or security breaches, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record (“EHR”) technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, physical risks from climate change or similar events beyond our control, (25) changes in U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to “Company” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

 

4

HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

Second Quarter

Unaudited

(Dollars in millions, except per share amounts)

 

     2022     2021  
     Amount     Ratio     Amount     Ratio  

Revenues

    $ 14,820       100.0 %    $ 14,435       100.0 % 

Salaries and benefits

      6,792       45.8       6,385       44.2  

Supplies

      2,301       15.5       2,380       16.5  

Other operating expenses

      2,693       18.3       2,473       17.2  

Equity in earnings of affiliates

      (8 )      (0.1 )      (22 )      (0.2 ) 

Depreciation and amortization

      738       5.0       712       4.9  

Interest expense

      434       2.9       386       2.7  

Losses (gains) on sales of facilities

      32       0.2       (8 )      (0.1 ) 

Losses on retirement of debt

      78       0.5       12       0.1  
  

 

 

    

 

 

    

 

 

    

 

 

  
     13,060       88.1       12,318       85.3  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income before income taxes

      1,760       11.9       2,117       14.7  

Provision for income taxes

      381       2.6       453       3.2  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income

      1,379       9.3       1,664       11.5  

Net income attributable to noncontrolling interests

      224       1.5       214       1.5  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc.

    $ 1,155       7.8     $ 1,450       10.0  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted earnings per share

    $ 3.90       $ 4.36    

Shares used in computing diluted earnings per share (millions)

      296.061         332.613    

Comprehensive income attributable to HCA Healthcare, Inc.

    $ 1,087       $ 1,466    
  

 

 

      

 

 

    

 

5

HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

For the Six Months Ended June 30, 2022 and 2021

Unaudited

(Dollars in millions, except per share amounts)

 

     2022     2021  
     Amount     Ratio     Amount     Ratio  

Revenues

    $ 29,765       100.0 %    $ 28,412       100.0 % 

Salaries and benefits

      13,731       46.1       12,686       44.6  

Supplies

      4,622       15.5       4,604       16.2  

Other operating expenses

      5,445       18.4       4,894       17.3  

Equity in earnings of affiliates

      (19 )      (0.1 )      (43 )      (0.2 ) 

Depreciation and amortization

      1,470       4.9       1,409       5.0  

Interest expense

      842       2.8       770       2.7  

Losses (gains) on sales of facilities

      22       0.1       (10 )      —  

Losses on retirement of debt

      78       0.3       12       —  
  

 

 

    

 

 

    

 

 

    

 

 

  
     26,191       88.0       24,322       85.6  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income before income taxes

      3,574       12.0       4,090       14.4  

Provision for income taxes

      730       2.4       846       3.0  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income

      2,844       9.6       3,244       11.4  

Net income attributable to noncontrolling interests

      416       1.4       371       1.3  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc.

    $ 2,428       8.2     $ 2,873       10.1  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted earnings per share

    $ 8.05       $ 8.50    

Shares used in computing diluted earnings per share (millions)

      301.690         337.940    

Comprehensive income attributable to HCA Healthcare, Inc.

    $ 2,317       $ 2,900    
  

 

 

      

 

 

    

 

6

HCA Healthcare, Inc.

Condensed Consolidated Balance Sheets

Unaudited

(Dollars in millions)

 

     June 30,
2022		     March 31,
2022		     December 31,
2021		  

ASSETS

       

Current assets:

       

Cash and cash equivalents

    $ 858     $ 2,371     $ 1,451  

Accounts receivable

      8,628       8,520       8,095  

Inventories

      2,043       2,003       1,986  

Other

      2,408       2,112       2,010  
  

 

 

    

 

 

    

 

 

  
     13,937       15,006       13,542  

Property and equipment, at cost

      52,816       52,042       51,350  

Accumulated depreciation

      (28,229 )      (27,814 )      (27,287 ) 
  

 

 

    

 

 

    

 

 

  
     24,587       24,228       24,063  

Investments of insurance subsidiaries

      379       408       438  

Investments in and advances to affiliates

      435       441       448  

Goodwill and other intangible assets

      9,593       9,525       9,540  

Right-of-use operating lease assets

      2,139       2,138       2,113  

Other

      514       462       598  
  

 

 

    

 

 

    

 

 

  
   $ 51,584     $ 52,208     $ 50,742  
  

 

 

    

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ EQUITY

       

Current liabilities:

       

Accounts payable

    $ 3,742     $ 4,010     $ 4,111  

Accrued salaries

      1,895       1,865       1,912  

Other accrued expenses

      3,116       3,157       3,322  

Long-term debt due within one year

      246       1,486       237  
  

 

 

    

 

 

    

 

 

  
     8,999       10,518       9,582  

Long-term debt, less debt issuance costs and discounts of $316, $323 and $248

      38,657       36,210       34,342  

Professional liability risks

      1,533       1,508       1,514  

Right-of-use operating lease obligations

      1,796       1,790       1,755  

Income taxes and other liabilities

      1,741       1,768       2,060  

Stockholders’ (deficit) equity:

       

Stockholders’ deficit attributable to HCA Healthcare, Inc.

      (3,680 )      (2,033 )      (933 ) 

Noncontrolling interests

      2,538       2,447       2,422  
  

 

 

    

 

 

    

 

 

  
     (1,142 )      414       1,489  
  

 

 

    

 

 

    

 

 

  
   $ 51,584     $ 52,208     $ 50,742  
  

 

 

    

 

 

    

 

 

  

 

7

HCA Healthcare, Inc.

Condensed Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2022 and 2021

Unaudited

(Dollars in millions)

 

     2022     2021  

Cash flows from operating activities:

     

Net income

    $ 2,844     $ 3,244  

Adjustments to reconcile net income to net cash provided by operating activities:

     

Increase (decrease) in cash from operating assets and liabilities:

     

Accounts receivable

      (547 )      (567 ) 

Inventories and other assets

      (462 )      (213 ) 

Accounts payable and accrued expenses

      (818 )      49  

Depreciation and amortization

      1,470       1,409  

Income taxes

      121       2  

Losses (gains) on sales of facilities

      22       (10 ) 

Losses on retirement of debt

      78       12  

Amortization of debt issuance costs and discounts

      15       14  

Share-based compensation

      171       226  

Other

      81       73  
  

 

 

    

 

 

  

Net cash provided by operating activities

      2,975       4,239  
  

 

 

    

 

 

  

Cash flows from investing activities:

     

Purchase of property and equipment

      (1,941 )      (1,496 ) 

Acquisition of hospitals and health care entities

      (116 )      (98 ) 

Sales of hospitals and health care entities

      20       30  

Change in investments

      (2 )      (12 ) 

Other

      (11 )      7  
  

 

 

    

 

 

  

Net cash used in investing activities

      (2,050 )      (1,569 ) 
  

 

 

    

 

 

  

Cash flows from financing activities:

     

Issuances of long-term debt

      5,966       4,337  

Net change in revolving credit facilities

      930       800  

Repayment of long-term debt

      (2,690 )      (3,731 ) 

Distributions to noncontrolling interests

      (333 )      (357 ) 

Payment of debt issuance costs

      (53 )      (32 ) 

Payment of dividends

      (337 )      (325 ) 

Repurchase of common stock

      (4,783 )      (3,814 ) 

Other

      (201 )      (224 ) 
  

 

 

    

 

 

  

Net cash used in financing activities

      (1,501 )      (3,346 ) 
  

 

 

    

 

 

  

Effect of exchange rate changes on cash and cash equivalents

      (17 )      3  
  

 

 

    

 

 

  

Change in cash and cash equivalents

      (593 )      (673 ) 

Cash and cash equivalents at beginning of period

      1,451       1,793  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 858     $ 1,120  
  

 

 

    

 

 

  

Interest payments

    $ 777     $ 755  

Income tax payments, net

    $ 609     $ 844  

 

8

HCA Healthcare, Inc.

Operating Statistics

 

     Second Quarter     For the Six Months
Ended June 30,		  
     2022     2021     2022     2021  

Operations:

         

Number of Hospitals

      182       187       182       187  

Number of Freestanding Outpatient Surgery Centers*

      126       122       126       122  

Licensed Beds at End of Period

      48,979       49,693       48,979       49,693  

Weighted Average Beds in Service

      41,930       42,464       41,875       42,413  

Reported:

         

Admissions

      515,113       532,041       1,022,069       1,038,421  

% Change

      -3.2 %        -1.6 %   

Equivalent Admissions

      902,757       916,212       1,762,047       1,748,701  

% Change

      -1.5 %        0.8 %   

Revenue per Equivalent Admission

    $ 16,417     $ 15,756     $ 16,892     $ 16,248  

% Change

      4.2 %        4.0 %   

Inpatient Revenue per Admission

    $ 16,727     $ 16,144     $ 17,207     $ 16,606  

% Change

      3.6 %        3.6 %   

Patient Days

      2,571,328       2,629,950       5,253,046       5,300,991  

% Change

      -2.2 %        -0.9 %   

Equivalent Patient Days

      4,510,739       4,535,678       9,056,251       8,926,869  

% Change

      -0.5 %        1.4 %   

Inpatient Surgery Cases

      130,961       136,460       257,841       264,050  

% Change

      -4.0 %        -2.4 %   

Outpatient Surgery Cases

      258,182       262,107       505,603       493,335  

% Change

      -1.5 %        2.5 %   

Emergency Room Visits

      2,223,999       2,128,428       4,280,388       3,970,206  

% Change

      4.5 %        7.8 %   

Outpatient Revenues as a

         

Percentage of Patient Revenues

      38.9 %      38.2 %      38.1 %      37.0 % 

Average Length of Stay (days)

      4.992       4.943       5.140       5.105  

Occupancy (weighted average beds in service)

      67.4 %      68.1 %      69.3 %      69.1 % 

Same Facility:

         

Admissions

      511,132       517,114       1,014,200       1,010,054  

% Change

      -1.2 %        0.4 %   

Equivalent Admissions

      892,948       888,402       1,742,396       1,695,881  

% Change

      0.5 %        2.7 %   

Revenue per Equivalent Admission

    $ 16,385     $ 15,838     $ 16,865     $ 16,365  

% Change

      3.5 %        3.1 %   

Inpatient Revenue per Admission

    $ 16,771     $ 16,236     $ 17,243     $ 16,693  

% Change

      3.3 %        3.3 %   

Inpatient Surgery Cases

      130,036       133,164       256,006       258,188  

% Change

      -2.3 %        -0.8 %   

Outpatient Surgery Cases

      250,420       253,982       490,644       478,887  

% Change

      -1.4 %        2.5 %   

Emergency Room Visits

      2,199,787       2,049,483       4,234,479       3,825,367  

% Change

      7.3 %        10.7 %   

 

*

Excludes freestanding endoscopy centers (21 centers at both June 30, 2022 and June 30, 2021).

 

9

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

Operating Results Summary

(Dollars in millions, except per share amounts)

 

     Second Quarter     For the Six Months
Ended June 30,		  
     2022     2021     2022     2021  

Revenues

    $ 14,820     $ 14,435     $ 29,765     $ 28,412  

Net income attributable to HCA Healthcare, Inc.

    $ 1,155     $ 1,450     $ 2,428     $ 2,873  

Losses (gains) on sales of facilities (net of tax)

      32       (6 )      24       (7 ) 

Losses on retirement of debt (net of tax)

      60       9       60       9  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt (a)

      1,247       1,453       2,512       2,875  

Depreciation and amortization

      738       712       1,470       1,409  

Interest expense

      434       386       842       770  

Provision for income taxes

      399       454       746       846  

Net income attributable to noncontrolling interests

      224       214       416       371  
  

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted EBITDA (a)

    $ 3,042     $ 3,219     $ 5,986     $ 6,271  
  

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted EBITDA margin (a)

      20.5 %      22.3 %      20.1 %      22.1 % 

Diluted earnings per share:

         

Net income attributable to HCA Healthcare, Inc.

    $ 3.90     $ 4.36     $ 8.05     $ 8.50  

Losses (gains) on sales of facilities

      0.11       (0.02 )      0.08       (0.02 ) 

Losses on retirement of debt

      0.20       0.03       0.20       0.03  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt (a)

    $ 4.21     $ 4.37     $ 8.33     $ 8.51  
  

 

 

    

 

 

    

 

 

    

 

 

  

Shares used in computing diluted earnings per share (millions)

      296.061       332.613       301.690       337.940  

 

(a)

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

10

EX-101.SCH 3 hca-20220722.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 hca-20220722_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 hca-20220722_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g383183g1.jpg GRAPHIC begin 644 g383183g1.jpg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
';J.]T^\3?#-'T89P00>000 M00>000:U*^>_V)[AI/A?JJNY(CUV4*I.=H,$!P/09)/XFOH/(KU\LQ;Q6#IU MVK.2/GL[R^.7YC6PL7=0=D_(6BBBNX\H_*'_ (+"?\E@\#?]BV__ *4O5C_@ MG7^UY\,OV>_A9XCT/XI:Q=Z9J&H>(6O;=(M-GN0\1MX4SF-2 =T;<'VJO_P6 M$_Y+!X&_[%M__2F2O"?V<_V'_'G[3_A/4O$/P_U3PE8V6EZD=/FCUB\N(9&D M$:2$J(X)!MQ(O)(.<\5[]*-.6"BJCLO^">-.4XXJ3@KL_2O_ (>;?L__ /0U MZC_X(;S_ .-U\L_\%$?VPOAA^T%\'-"\/?"[6;S4M3LO$T.H3QRZ9/;*L"VU MS&3ND4 G=*@P.>3Z5R7_ Z)^,G_ $,/PS_\&E[_ /(=>5_M&?L,>/OV8?!= MCXG^(&J>$;ZPU#5$TR&/1[RXFE$KQ2R L)((P%VPN,Y)R1QSD1AZ6#52+A*[ M+K5<2Z;4HV1[1_P2!_Y+IXQ_[%)__2NWKYW_ &S/'=U\1/VH?B/J=\Q86NNS MZ9;+DX6&T;[/'@=LB+]?1'_ 2!_P"2Z>,/^Q3?_P!*[>OE+]H[39M) M_:"^)EG=(T%VL[:$:SXLL(-9UF\"8DGDG021QL3SMBC=4 Z9#-C+,3]%5YQ^S?XJ MM?&GP"^'FL:;+%+%>>&;'>8^B2K"J2I]5D5E(]5->CU\_5E*523EN>U324$E ML>:?M#? ?0OVBOAAJ?@[Q4%A%R!+I^H"$22:==J#YHZ#:S:[XL\LI+XAU/#3(&7#K @^6%#\PXRY#%6=A7O>IZ MG::+I]U?ZO=6]E8V4+S7-S<2B..&- 69W8\*H ))/ I]E?6^I6<-WIT\-U: MW*"2&:&0.DB$9#*PX((YR*%5J*'(GH)TX.7,UJ*/&>L>6; M;P[ILMTL;OL$\H&(H0V#@O(40'U85^$?PG\%ZM^T=\?M"T&_N)[G4O&VO&75 M;Q0/,".[37<^"0"5C$LF.^*_0'_@KI\9/[)\'^&/AII5SBYU^"_V;/B5JGB[XA:/KNLW1TMK/2DTR&%_(:1 MU,LC>8Z8;:H4$9X=\UZ^!IRAAY5(K5['FXNI&591;T1])_\ !6OX)6VBP^!/ M'WAVTCMK*WMAX:O(X@%2)8PTMF%4=!M%PI/HJ#TK6_X)"_&(36?BWX8:G,3) M;M_;NDJV2?+;9#0P7J2\A[&NVU+]IKP7_ ,%"O ?CCX1^"?#7BFRU MNX\.3:I83ZE';I$MQ;21-""Z2L5W3&)3Q]UF'>OSF_9K^+,GP(^.WA+QA(9( M[72=0":FFPEC:2@Q7 V]V$;N0/[P'I3ITY5,+*E->\OZ0ISC#$*I'9G]!#'" MDU\?_$C]H;XF7'B>\A\#Z9>Z5I-K,T=NW]CF62X4'&]S(AQG&0 !C=@YQFOK MR.1)K=)(762.1 R.IR&!'!![BOD?Q]^T]\2OA[XHO=&US1O#-NUO,XMWDL9\ M7$0/RR(?.PP(PNK(-^^CM8Y89&'^RS2, ?\ @)K=?X.>#KJ\'Q4&K72^!'M3JQFYU,/-UIR5I\^EH=7_F[Z=C[O-/K M-.-*CC*2PU.#YJ:II24JJ^%/;Y*ROK[VAY;X=OOBI\%[Z^LM#L];TMYW_?PG M3A<12,O&]A^ ?VC/B;I_B*U'C32[[6-*GF1+@?V.8I(4)P M70QH,D9!P0&Q ME2R>BY6U]U_T.C,<'F&)P\ZV-RVC=KWI.:36F][75O4^P5^[3J:OW13J_4#\ M)/RA_P""PG_)8/ W_8MO_P"E,E>W?\$@?^2$^,/^QND_]([:M;]O/]B/QO\ MM1>./#6M_#_5_"UA!H^E/9W,>LW$\+%C*7#)Y<,@(PV.<=.]>A_L'_LT^)_V M7_AIKOA[Q]?Z%J%]JFO/J$4FCSRRQ+$8(8P&,D<9W;HVX QC'/IZ^% M&C^%_ =]HFGW^G^(H=2DEU>:6*(Q);W$14&..1MV9E/0# //8\F$G&%:,GLC MJQ$7*E)+<^)O^"0/_)=/&'_8IO\ ^E=O5S_@JI^S??>'?'L?Q:\.VDD^A>)% MBM]<:-Z3XBL;74]-U&%H+ MJSNHA)%/&PPRLIX((KKJXM0Q7M(:HYJ>&%?'5 ME?:_X#GF:>&.T93=:5*W+F%7(5XW/+1EEPQ+ @E@_P"@,/\ P4B_9[DT\73> M/&C.S<;=M"O_ #%/]W @()^A(]Z^=OC=_P $BX-0U.?4?V?_ !+:Z7;S2;AH M?B R/%!DDD1W2!Y-H& %=&;@YT::$/M%TFNVXC( M_O8+!\?\!S[5O.."KOGYK/[C&,L517+:Z.L_;6_X*(2?'O0YO!'PKL;[1O!L M\BMJ5[>X2ZU380RQA%)$4.X!NI9\+G:-RGNO^"2_A;XA7WB#6=?CU[5K#X:: M9%);OI;2%K74K^0+]R-@54QKAVD3:V?+7)5G TO@O_P2)NH]4@OOCWXILI+& M)@S:-X=,C&X'7#W,BJ4&>"$0DYX=>M?<7C_X5WEC^S_K7@+X!V^A^&+N71I- M,T59FD@MK)9?ED?=&K.'VO(P;!)?#-DDFLZ^(H1I^QI=>I=*C6E4]K4Z=#\6 M?VN/C'_PO?\ :"\6^*;.8SZ2UW]BT8@G;]B@'EQ,H/(#[3*1V,C5]:>#_P#@ MD#?:YX5T;4M?^)#Z-J=_80W%YIO_ C?FFSE= SPE_M*[BI)7.!G'2F_!G_@ ME'X[\+_%;PKK/Q*UOP->^&-'U2*]O[6PNKF>6Y6([UBV26RHRNRJK98?*S8R M<5^H@IXG&J$8PH2T0J&%YW*55;G@G[*_['?A+]E?2+\>';J[UOQ!K*HNI:S> M1JC.B\K%%&.(H\DL1EB3C)[>SC,6D^*&&O M:<.,!+EF,J@ +.LRA>RA:_ [W1=-\2^';J5/. MU::2*&6SF4%U+1Q2,762.(J,8PTG0T2DGJR/[U].26\4& MOBO]@_\ 8[^)W[+/C3Q)<>-M;\'W_AKQ%IJ1R6ND7=Q+-]KBD!AD(D@0!0DE MP#\V'M.C\!Z5JL=I;IJ$6K) M MPL8#^6\4K,A(ZC**?PKEH<_\,-W7/_+R,>W_ !,4KZ&^+GPSM?BMX+N=#O)V MM93(L]I9)Y M&T7:S==F[.P?W>O?O7Q&897B'CZ]:G#W9TI+3^;MZGZ9E&?82.4X7#5JEI4\ M1"3O?2&]_1'._L4>'=-F\%ZUJTUG;R:B=6:V^T.@9EB6*)@H)Z#+L??CT%?2 M<=K'%GRD1,]=JXS^5<7\'/AC;?"?P;%HMK.;N9Y6N+RX*[?-F8 $A]=S7N9-@Y87 TJ4U:26OJ?+<2YC#'YK7Q%.3<)/2_;H(.*6BBO4/"/G7]K M_P"*_P 6?@;X+O?&_P ,;/P%J?AC1+6)M4M=:CNC>B1Y_+WQ&.149,/%\IPP M^8Y/ J']CGXP?%7X^^"['QU\1+;P#I_A368;E=.MM&ANUOO-AN&A+2&21HPF M8Y>!DGY3D5M_P"ED%>(?L+_ +5GPR^&O[+7@KPYXRUO M4[/6-.-_]IAA\-ZE=*OF7]Q(N)(;=D;*NIX8XS@X((KLC3YL-=1N[V_ Y93Y M:]G+2QW7[:G[1GQC_9CM4\4^&=-^'.K^![V_AL+9;R&\.H03/"SGS0LJQLA: M.3!7! V@CO7K7[,_B_XE?$/P'8>*OC G@BWMO$FF66HZ+:^'(KI7ABFC,A%P MTSL"VUX^$X!#'[^R4 M1+#<*3YD\"(3EUX!R<].#7M&K?M'2_ /]E'X'67A338=>\>^./#FC:7X7TF= MBL4T[6ENIEE8$'RT:2($ @L9% *@EEMT6Z,4H^\V2JJ567O:)'U[2U\B?&B\ M^/G[/WPLNOB0WQ*TKQM<>'_+N-;\,W/A>WM;*6%W5'%O+%MG7R]^07<[@I)_ MNF+X\_MR7?A#]F'P3\2_A/X?75+_ .(%Q':6,=X'EAT^8J_FHX3!ED5XGC50 M5#$%NB[6YUAY2MRZWT-G6BKWTL?7^*\/_:H\ ]2\7_!J'P+?:?X^U>S\00W+3M'$-[-"T4J+\J!B5;!..#G KQK]ICQ_\:OV3O"F@_$!/B);_ M !!T8:E#9:UH.K^&[2P5Q(C-OBDMU62/[A 4LQ!*D[P&!]O_ &@-?MO%?[(? MQ"UO3-_V/6/AYJ%Y;[QAO+EL'=H37L6EPND*);W,T8V*[LV=D0SECDYZ5U/P,^.WAK] MHCP2_BGX>_VC_9<=])9'[=;B&3S452WR@GC#KSGUKY3_ &9[+QMT/18[+3O$,NJ)J6D/?&ZB%W=$)&5EC\MN&Y.[J..*YK_ ()GZ'\3M2^! MAG\!^+?"^C^'8?%,XNK"_P##LEY<2D) 9"LRW"!=RE0!L.",\]*VJ8>%IR3M M9_YF4*TO<5KW1Z7\9/VD/C;\%/V@OAIX0\1V7PUOO"7Q*\30:?8WME9W@NX[ MG!%?9:U\%?\%&KRZT[X^?LKW>DV#ZK?6WBV:6U MT^.9(GO)%O-+985=R$4L0%!8@ G)-;/[3GBC]IKX+^"+GXI6WCCP6=+TBYMV MU3P?8Z"LEO;PR2I$JBZE'G3_ #.@+_C[\$OV?[KXM^+OB%I8UZQDLKFZ\%P>%[8Z;"+BXBC-H9B M3<'8)>7$N25('9JQCAYO?36WS-77BOS/M2BOC#XT?MT:]X7_ &8?AW\0/A_X M2DG\0?$EUMH(KF%Y[;3IP&$@PI5I69U81+E=XRQ^Z5-?]ISXC?&7]D'0?#GC MN3XAVWQ%\/RZM%I^M:+JWAZTL2PD1WWPRVZJR<1LHW;MK%2=XR*<<--V6S?Z M Z\5KT1]KTFT>E>'?M%^,O'%C\";[Q_\#M?T33AH^A3:Y-#JNDM=?;K581, MCB0")A&'/*.&)4?*,FOF?1_CO^T]\3OV1['XA_#T6*ZG:SR*3IVAQZAJ&ND7 MKQ,8;8 I%!&A53\CRLT+G"+\[*&'E./-=;V"=:,96L^Y^A-!KX^7]H_XC_$S MQQX-^$'P^&F>&?'[>$K36_B)KE[8&8>'6>"%Y(8+5V :;S)HAARP42J.2&9( M/B5\5[=>P>WC:_0];N_VP/AY8,ZWEW?QN)-3BCC6%))));")))83 M&CEXYF$BA(90DC,0NT%E!]AT/5[?Q!HMAJFGES:ZE:QW,!=<$I(H9;/9)*RMOBD4@MG&UX(67&-IC4KC KKK&Q@TRQM[ M/3XDM[6TB6*"*-<+&B@!5 [ 5G)P^R7'FZG@'_ 4 _P"3/?B1_P!>5M_Z M605F_P#!-W_DS#X>?]Q/_P!.=U76_M$?L\ZA^T-I-QH%]\0?$'ASPK>VT45_ MHNG6-HR7TA]6Y+ZWO\ H9*[ MU"SNVMI+$(+)II4E4@QN(W5@PY&S(Z5]I?M'_LBS_M,.UEXP^)'B:Q\+I=Q7 MEGX?L]/LQ#:S)#Y>\2^5YKYW2-AW8 N<8 &(;?\ 8OTC5O@[/\,?BIXM\0>. M?"UO!;1Z"M];VL%QH#0!T22WGCC#EMKA1YABCB*=.$4WJF_Q,JM M&=24K+?]#0UC]C/PIXETFZTWQ!XT^+FJZ9>QF*YL[SQY>SPSH?X71G*L/8BO M+_B=\:M+_9$^'?PT^%_[+=EIGB?4?%NL7>D^'YK_ %/[5:6&-%3PJW[0_CF3P)$GD1Z9;Z5:Q7\<'18DU% MM\J !1L"@#@!16I\;/V'O!?Q8\ ^#/#OA6YO/ 4_P /,GPO?:3ES8ABC,&5 MF#2$M&C[]XDWKNWY9MV<9PYDIRNBG&3BW"-F?/?_ 4*^%.O>&_V:8=>^)GQ M \2^,_$;ZS90/$72PTJW)$K'R;&%54G V[Y3(_'!&<5]'^.D$7[ .M(#D)\( MY1GZ:4:Q/&W[$Q^+WP_N]$^.GQ,\7>-=9\E%TS5&A@L8-*D1MPEBLXE$;R,, MHSREW*,P5DR36G_PRKXJNO@JGPUUKXT^*[K2S9MIMQ-%HNGQ--IYA6);7)B: M0*%!RYD+G)RV.*'5AR13EL^PHPES2:CNCA_V-/\ E&];_P#8#\1?^E-Y5+_@ MDO(K?LPZB 02OBZ\#<]/W%L?Y&O8?V>_V8_^&?\ PI=>$X?&FN^*?"$L,J0: M)JMI;"*V:5LRE'1!)ALME"VW+,<9)->;?"_]@6\^#M_JMO\ #OXT?$+0?".J MW!GDT6Q2W64.0%W>>ZLH?"J"ZQ*Q"@$\"G.K3DJD;[NX0A./([;*QRG[?W_) MRW[(_P#V/!_]+]*KU_\ X*#D?\,<_$?_ *]+3_TM@K*^-7[%]Q\>*ZCXP?LW:Q\;/A MC9^"O%7Q.\21Z>\)CUN:WTNP1]983)+$TF(1Y6QHP,1; P)W U$:E/\ =>]\ M.^_>Y7+/]YIO_E8_/;]IBSN[;]CG]E777MI9]'TN*ZCO,?=\R0Q/&I]V6";' MT-?K2/['\;>'8W*V&M:'K-JDB^8BSV]W!(H93@Y5D92#Z$&O"_"G[&VB:9\% M=0^%'Q \2:UXX\&3Q1II=KJ%O;P2Z.5>1]\$T2!RV]P1O+ !0H&PLIYOP-^Q M?XS^'^C-X5T+X_\ CJU^'RLRQ:-;:;:I>P1$_P"KBOV#/$./^6:J.20!DU=6 MI3JQMS6LW^.HJ4)P=[7NE^ W]IC]K0?""Z\#> _@#9^%]<\5^,M6.B:?YDX. MGZ0\<\=L8Y4A(.X2OY>P$;-C9' 4^(?\%&/A7KGA;]G#3M;^(GC_ ,3>-?$D M_B*SMG$K)8Z9!F*X),%C %C!P -\AD?@X89(KZ)^-'["O@OXF>#O!6C>";N\ M^'M[\.W+>&]1TE3(UKN=7;>&8/(QD02;RX??EMQ+-FCXZ_8C7XQ>!;G1OCC\ M2?%OC37F1!INKR0PV5OI;HV[?#90@1,S ['>3>Y7A63)IT:M&')).UM^XJE. MI/FBUZ'5?$Z/R?V&?%,>0?+^%-VN?7&E-7-_\$V/^3,? 8/42:G_ .G*YK4G M_9?\5:E\%4^&^N?&;Q7=V$EH^GWEU'H]A&]Q8&%8A:DF)G"[0_4M1E[12MI:Q\=>!?A_#K/\ P4R^*_AKQYXE\3Z!=:S9 MW-UI=QH>N3:9<78ZAHVB;K@W'B3QQ<2V]EG :3=,VU., G(KJ/VC/V0_#/[0&J:1XB_M36/"'C MCP\H&E^)=%EV3Q*K%E5QQN569F&"K DX8 D'/T/]EOQ#KEYIH_:%^*VO?%'2 M]%N8[JST5])MM(L99HR#&UU'!EKK:P5@LC% GRAPHIC 7 g383183g2.jpg GRAPHIC begin 644 g383183g2.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jul. 22, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000860730
Document Type 8-K
Document Period End Date Jul. 22, 2022
Entity Registrant Name HCA HEALTHCARE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-11239
Entity Tax Identification Number 27-3865930
Entity Address, Address Line One One Park Plaza
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code (615)
Local Phone Number 344-9551
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $.01 par value per share
Trading Symbol HCA
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 9 d383183d8k_htm.xml IDEA: XBRL DOCUMENT 0000860730 2022-07-22 2022-07-22 false 0000860730 8-K 2022-07-22 HCA HEALTHCARE, INC. DE 001-11239 27-3865930 One Park Plaza Nashville TN 37203 (615) 344-9551 false false false false Common Stock, $.01 par value per share HCA NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d383183d8k.htm d383183dex991.htm hca-20220722.xsd hca-20220722_lab.xml hca-20220722_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d383183d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d383183d8k.htm" ] }, "labelLink": { "local": [ "hca-20220722_lab.xml" ] }, "presentationLink": { "local": [ "hca-20220722_pre.xml" ] }, "schema": { "local": [ "hca-20220722.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hca", "nsuri": "http://hcahealthcare.com/20220722", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d383183d8k.htm", "contextRef": "duration_2022-07-22_to_2022-07-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d383183d8k.htm", "contextRef": "duration_2022-07-22_to_2022-07-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hcahealthcare.com//20220722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-199606-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-199606-xbrl.zip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